Agha M et al. Efficacy and safety of the BCMA-directed CAR-T cell therapy, ciltacabtagene autoleucel, in patients with progressive multiple myeloma after 1-3 prior lines of therapy: Initial results from CARTITUDE-2. EHA 2021;Abstract S190
Bahlis NJ et al. Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). ASCO 2021;Abstract 8006
Bal S et al. Clinical activity of BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed and/or refractory (R/R) multiple myeloma (MM): First results from a phase 1, multicenter, open-label study. ASH 2022;Abstract 364
Cortes-Selva D et al. Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Correlative analyses from MajesTEC‑1. ASH 2022;Abstract 97
Du J et al. Phase I open-label single-arm study of BCMA/CD19 dual-targeting FasTCAR-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma. ASH 2022;Abstract 366
Einsele H et al. Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: CARTITUDE-2, cohort A. ASCO 2022;Abstract 8020
Lonial S et al. Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study. ASCO 2022;Abstract 8019
Lonial S et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer 2021;127(22):4198-212. Abstract
Mateos M-V et al. MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator’s choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma. ASCO 2022;Abstract TPS8072
Moreau P et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022;387(6):495-505. Abstract
Nooka AK et al. Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1. ASCO 2022;Abstract 8007
Paiva B et al. Early and sustained undetectable measurable residual disease (MRD) after idecabtagene vicleucel (ide-cel) defines a subset of multiple myeloma (MM) patients in karmma achieving prolonged survival. ASH 2022;Abstract 868
Pihlgren M et al. ISB 2001, a first-in-class trispecific BCMA and CD38 T cell engager designed to overcome mechanisms of escape from treatments for multiple myeloma by targeting two antigens. ASH 2022;Abstract 353
Reyes KR et al. Clinical outcomes and salvage therapies in patients with relapsed/refractory multiple myeloma following progression on BCMA-targeted CAR-T therapy. ASH 2022;Abstract 250
Samur MK et al. Differences in single cells between BCMA-targeting CAR T-cell therapy responders and non-responders reveals initial resistance and acquired resistance are driven by different factors. ASH 2022;Abstract 869
Terpos E et al. Safety and efficacy of belantamab mafodotin in combination with Rd in newly diagnosed, transplant ineligible multiple myeloma patients: A phase 1/2 study by the Hellenic Society of Hematology. EHA 2022;Abstract S178
Usmani S et al. KarMMa-2 cohort 2a: Efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation. ASH 2022;Abstract 361
Usmani SZ et al. DREAMM-9: Phase I study of belantamab mafodotin plus standard of care in patients with transplant-ineligible newly diagnosed multiple myeloma. EHA 2022;Abstract P942
Usmani SZ et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study. Lancet 2021;398(10301):665-74. Abstract
van de Donk NWCJ et al. Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma and early relapse after initial therapy: CARTITUDE-2, cohort B. ASCO 2022;Abstract 8029
Zonder J et al. Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMA x CD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multiple myeloma. International Myeloma Society 2022;Abstract OAB-056